Novo Nordisk A/S Sponsored ADR (NVO)
NVO Challenges LLY Ads in GLP-1 Battle: Why the Lawsuit Matters Now
Novo Nordisk sues LLY over high-profile ads promoting Zepbound and Mounjaro, arguing newer clinical data changes the comparison as the GLP-1 rivalry intensifies.
Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo Nordisk's Rally Has Room To Run Driven By Oral Wegovy's Momentum
Novo Nordisk shares have rallied approximately 27% since my previous coverage, driven by accelerating commercial momentum behind oral Wegovy and expanding investor confidence. Oral Wegovy captured roughly 89% of new U.S. prescriptions versus Eli Lilly's 11%, with 153,050 weekly prescriptions compared with 19,550. More than 80% of oral Wegovy prescriptions came from new GLP-1 patients, expanding the overall market instead of cannibalizing injectable products.
Does EU Approval of Wegovy Pill Change NVO's Competitive Story?
Novo Nordisk wins EU approval for the first GLP-1 obesity tablet, expanding Wegovy's reach, but tougher competition keeps the broader investment outlook in focus.
Novo Nordisk: The Oral Wegovy Promise
Novo Nordisk has made robust gains of 40% at the stock markets since April, supported by the success of oral Wegovy and attractive valuations. The Wegovy pill can see a nice revenue uptick in Q2 2026 going by recent data, and that can continue into the year as it gains approvals from international markets. Importantly, the pill has made gains even when competitor Eli Lilly's Foundayo has seen limited success, which can give Novo Nordisk a much-needed boost.
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
Novo Nordisk (NVO) closed the most recent trading day at $51.48, moving +1.82% from the previous trading session.
NVO Stock Up on EC Approval of Wegovy Pill to Treat Obesity
Novo Nordisk wins EC approval for a once-daily oral Wegovy pill for obesity, expanding its EU franchise with the first GLP-1 tablet for weight management.
NVO Rallies 11% in a Month: How Should Investors Play the Stock?
Novo Nordisk stock gains 11% in a month as Wegovy access expands and U.K. approval boosts optimism, but rising competition and earnings pressure cloud the outlook.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo Nordisk launches weekly insulin Awiqli in India as diabetes burden rises
Danish drugmaker Novo Nordisk launched its weekly basal insulin injection, Awiqli, in India on Thursday, where diabetes rates are among the highest in the world.
Novo Nordisk (NVO) Dips More Than Broader Market: What You Should Know
Novo Nordisk (NVO) reached $48.89 at the closing of the latest trading day, reflecting a -1.51% change compared to its last close.
Leading bank backs European pharma as the cleaner alternative to the AI trade
UBS has reiterated its overweight stance on European pharmaceuticals, framing the sector as a more resilient home for capital than artificial intelligence at a point when the wider market is slowing. The bank argued that the investment case now rests on more than defensive quality.
